CA Anzar, Joseph MV, Sundaram, Vadiraj GB* and Shariq Afsar

Indusviva Health Sciences Private Limited, Jayamahal Extension, Bangalore, Karnataka, India

*Corresponding Author: Vadiraj GB, Indusviva Health Sciences Private Limited, Jayamahal Extension, Bangalore, Karnataka, India.

Received: March 12, 2024 ; Published: March 21, 2024

Abstract

The main cause of cardiovascular disorders is atherosclerosis, an inflammatory pathology of the vasculature. To reduce the morbidity and mortality of this illness, a wide range of therapeutic and preventative measures are being investigated. However, a few of the treatments were quite expensive and caused a number of negative side effects. The aim of the present study was to assess the anti-atherosclerotic properties of the herbal formulation I-PULSE+ in order to ascertain the modulatory potency of the anti-atherosclerotic effects on the PCSK9 gene expression levels in the HepG2 cell line. The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) assay was used to evaluate the cytotoxicity of I-PULSE+ in the Human Hepatocellular Carcinoma Cell Line (HepG2) at different concentrations (1000 to 62.5μg/ml). The impact of the I-PULSE+ anti-atherosclerotic effect on the PCSK9 gene was determined using a semi-quantitative gene expression method. This method indicated the transcript level of PCSK9 in the human hepatocellular carcinoma cell line (HepG2) in comparison to untreated HepG2 cells. I-PULSE+ exhibits a CTC50 value of >1000 μg/mL on the HepG2 cell line. The results of the gene expression analysis indicate that PCSK9 gene expression was significantly reduced by I-PULSE+ at lower concentrations (62.5 and 125 μg/mL) as compared to the control. The results of this study indicate that I-PULSE+, a herbal formulation, may function as a potential nutraceutical agent to manage atherosclerosis.

Keywords: I-PULSE+; Herbal Formulation; PCSK9 Gene Expression; HepG2 Cell Line; Anti-Atherosclerosis Effect

References

1. Fishbein G A and Fishbein M C. “Arteriosclerosis: rethinking the current classification”. Archives of Pathology and Laboratory Medicine 8 (2009): 1309-1316.
2. Xu Y., et al. “Identification of dehydroxy trichostatin A as a novel up-regulator of the ATP-binding cassette transporter A1 (ABCA1)”. Molecules9 (2011): 7183-7198.
3. Pearson TA., et al. “AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to comprehensive risk reduction for adult patients without coronary or other atherosclerotic vascular diseases”. Circulation 3 (2002): 388-391.
4. Libby P., et al. “Inflammation and atherosclerosis”. Circulation 105 (2002): 1135-1143.
5. Van Gaal LF., et al. “Mechanisms linking obesity with cardiovascular disease”. Nature 444 (2006): 875-880.
6. Galkina and Ley K. “Immune and inflammatory mechanisms of atherosclerosis”. Annual Review of immunology 27 (2009): 165-197.
7. Du S., et al. “TRPC5 in cardiovascular diseases”. Reviews in Cardiovascular Medicine 1 (2021): 127-135.
8. Robinson JG and Davidson MH. “Can We Cure Atherosclerosis?”. Reviews in Cardiovascular Medicine 19 (2018): S20–S24.
9. Hanna-Moussa A., et al. “Dysglycemia/prediabetes and cardiovascular risk factors”. Reviews in Cardiovascular Medicine 4 (2009): 202-208.
10. “The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies”. The Lancet 375 (2010): 2215-2222.
11. Ross S., et al. “The Genetic Link between Diabetes and Atherosclerosis”. The Canadian Journal of Cardiology5 (2018): 565-574.
12. Andrew V. Memorial-Sloan Kettering Cancer Center, New York, NY, Catherine Zollman, Clinical lecturer in general practice, Bristol University, Bristol, UK, Roberta Lee, Beth Israel Health and Healing Center, Boston, MA: Herbal medicine, (ISBN 0 727912372) London: BMJ Books; 2000, edited by Dr Zollman and Dr Vickers.
13. Sameer Al A., et al. “Supercritical fluid extraction of useful compounds from sage”. Natural Science 8 (2012): 8.
14. Kanungo SK., et al. “Comparative evaluation of hyperlipidemic activity of some marketed herbal formulations in triton induced hyperlipidemic rats”. Pharmacologyonline 3 (2007): 211-221.
15. Barter P. “The role of HDL-cholesterol in preventing atherosclerotic disease”. European Heart Journal Supplements 7 (2005): F4-F8.
16. Palombo C and Kozakova M. “Arterial stiffness, atherosclerosis and cardiovascular risk: pathophysiologic mechanisms and emerging clinical indications”. Vascular Pharmacology 77 (2016): 1-7.
17. Nicholls SJ., et al. “Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial”. 316. 22 (2016): 2373-2384.
18. Tang ZH., et al. “New role of PCSK9 in atherosclerotic inflammation promotion involving the TLR4/NF-κB pathway”. Atherosclerosis 1 (2017): 113-122.
19. Feingold KR., et al. “Inflammation stimulates the expression of PCSK9”. Biochemical and Biophysical Research Communications 374 (2008): 341-344.
20. Bulbulia R and Armitage J. “LDL cholesterol targets how low to go?”. Current Opinion in Lipidology 4 (2012): 265-270.

Citation

Citation: Vadiraj GB., et al. “Evaluation of Anti-Atherosclerotic Potential of Herbal Formulation iPulse+ through modulation of PCSK9 Gene Expression in the HepG2 Cell Line: An In vitro Study".Acta Scientific Pharmaceutical Sciences 8.5 (2024): 71-76.

Copyright

Copyright: © 2024 Vadiraj GB., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.